US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
PL1912675T3
(pl)
|
2005-07-25 |
2014-10-31 |
Emergent Product Dev Seattle |
Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
|
AU2013202375B2
(en)
*
|
2005-12-16 |
2016-10-27 |
Amgen Research (Munich) Gmbh |
Means and Methods for the Treatment of Tumorous Diseases
|
EP1976886B1
(de)
*
|
2005-12-16 |
2014-12-17 |
Amgen Research (Munich) GmbH |
Mittel und verfahren zur behandlung von tumorkrankheiten
|
RU2008129827A
(ru)
*
|
2005-12-21 |
2010-01-27 |
МЕДИММЬЮН, ЭлЭлСи (US) |
МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
|
JP5399712B2
(ja)
|
2005-12-21 |
2014-01-29 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
可溶性ceaに対する抵抗性を有する医薬組成物
|
JP2009531324A
(ja)
|
2006-03-20 |
2009-09-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
癌標的化のための操作された抗前立腺幹細胞抗原(psca)抗体
|
NZ596865A
(en)
|
2006-06-12 |
2013-07-26 |
Emergent Product Dev Seattle |
Single-chain multivalent binding proteins with effector function
|
WO2008076487A2
(en)
*
|
2006-12-20 |
2008-06-26 |
Verenium Corporation |
Antibodies and methods for making and using them
|
AU2013202392B2
(en)
*
|
2006-12-20 |
2016-02-25 |
Mmrglobal, Inc. |
Antibodies and methods for making and using them
|
DE202007016718U1
(de)
*
|
2007-02-21 |
2008-04-03 |
K.L. Kaschier- Und Laminier Gmbh |
Airbagdeckelscharnier mit kraftaufnehmendem System
|
AU2008234020B2
(en)
*
|
2007-04-03 |
2013-02-07 |
Amgen Research (Munich) Gmbh |
Cross-species-specific CD3-epsilon binding domain
|
WO2008119566A2
(en)
*
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
US8940298B2
(en)
*
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
JP5951929B2
(ja)
*
|
2007-10-03 |
2016-07-13 |
コーネル ユニヴァーシティー |
Psma抗体を用いる増殖性障害の治療
|
CN102099377A
(zh)
|
2008-04-11 |
2011-06-15 |
新兴产品开发西雅图有限公司 |
Cd37免疫治疗剂及其与双功能化学治疗剂的联合
|
US20100069616A1
(en)
*
|
2008-08-06 |
2010-03-18 |
The Regents Of The University Of California |
Engineered antibody-nanoparticle conjugates
|
HRP20160857T4
(hr)
|
2008-10-01 |
2022-12-09 |
Amgen Research (Munich) Gmbh |
Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene
|
MX338038B
(es)
*
|
2008-10-01 |
2016-03-30 |
Amgen Res Munich Gmbh |
Anticuerpo de una sola cadena bis-especifico de pscaxcd3, cd19xcd3, c-metxcd3, endosialinaxcd3, epcamxcd3, igf-1rxcd3 o fapalfaxcd3 de especies cruzadas.
|
KR101820535B1
(ko)
|
2008-10-01 |
2018-01-19 |
암젠 리서치 (뮌헨) 게엠베하 |
종간특이적 psmaxcd3 이중특이적 단일쇄 항체
|
ME02363B
(me)
*
|
2008-11-07 |
2016-06-20 |
Amgen Res Munich Gmbh |
Liječenje akutne limfoblastične leukemije
|
LT2918604T
(lt)
*
|
2008-11-07 |
2018-03-26 |
Amgen Research (Munich) Gmbh |
Vaikų ūminės limfoblastinės leukemijos gydymas
|
WO2010096486A1
(en)
*
|
2009-02-17 |
2010-08-26 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
IN2012DN03172A
(de)
|
2009-09-18 |
2015-09-25 |
Micromet Ag |
|
CA3040276A1
(en)
|
2009-12-02 |
2011-06-09 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
TWI653333B
(zh)
*
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
跨物種專一性之PSMAxCD3雙專一性單鏈抗體
|
BR112013010544A2
(pt)
*
|
2010-10-29 |
2016-08-02 |
Immunogen Inc |
moléculas de ligação ao egfr e imunoconjugados das mesmas
|
JP2014500879A
(ja)
|
2010-11-16 |
2014-01-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Bcma発現に相関性を有する疾患を治療する因子及び方法
|
US9249217B2
(en)
|
2010-12-03 |
2016-02-02 |
Secretary, DHHS |
Bispecific EGFRvIII x CD3 antibody engaging molecules
|
US10239952B2
(en)
|
2011-04-01 |
2019-03-26 |
Memorial Sloan Kettering Cancer Center |
Anti-WT1/HLA bi-specific antibody
|
SG194510A1
(en)
|
2011-04-22 |
2013-12-30 |
Emergent Product Dev Seattle |
Prostate-specific membrane antigen binding proteins and related compositionsand methods
|
DE102011118022B4
(de)
*
|
2011-06-30 |
2018-01-18 |
Gemoab Monoclonals Gmbh |
Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
|
CN102337298B
(zh)
*
|
2011-08-19 |
2013-11-06 |
黄开红 |
一种输送siRNA的免疫纳米载体及其制备方法和应用
|
KR101681818B1
(ko)
*
|
2011-08-23 |
2016-12-01 |
로슈 글리카트 아게 |
T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
AR089114A1
(es)
|
2011-12-09 |
2014-07-30 |
Amgen Res Munich Gmbh |
PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
|
AU2013208895B2
(en)
|
2012-01-13 |
2017-07-06 |
Julius-Maximilians-Universitat Wurzburg |
Dual antigen-induced bipartite functional complementation
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
US20150037334A1
(en)
|
2012-03-01 |
2015-02-05 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
JP6154895B2
(ja)
*
|
2012-06-07 |
2017-06-28 |
デューク ユニバーシティー |
ヒト二重特異性EGFRvIII抗体結合分子
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
US9682143B2
(en)
*
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
CN104379169A
(zh)
*
|
2012-08-14 |
2015-02-25 |
Ibc药品公司 |
用于治疗疾病的t-细胞重定向双特异性抗体
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
MX362456B
(es)
|
2012-08-24 |
2019-01-18 |
Univ California |
Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
|
JOP20200236A1
(ar)
*
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
MX369276B
(es)
*
|
2012-11-13 |
2019-11-04 |
Biontech Ag |
Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
|
EP2964675B1
(de)
*
|
2013-03-05 |
2018-06-20 |
Baylor College Of Medicine |
Engagerzellen für die immuntherapie
|
AU2014280123B2
(en)
|
2013-06-14 |
2019-11-14 |
Akamis Bio Limited |
A dosing regime and formulations for type B adenoviruses
|
RS63152B1
(sr)
|
2013-07-25 |
2022-05-31 |
Cytomx Therapeutics Inc |
Multispecifična antitela, multispecifična antitela koja mogu da se aktiviraju i postupci za njihovu upotrebu
|
CN104342453A
(zh)
*
|
2013-08-06 |
2015-02-11 |
深圳先进技术研究院 |
含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
MX2016003744A
(es)
|
2013-10-11 |
2016-08-11 |
Us Health |
Anticuerpos tem8 y su uso.
|
AU2014338864C1
(en)
|
2013-10-25 |
2020-07-16 |
Akamis Bio Limited |
Oncolytic adenoviruses armed with heterologous genes
|
JP6553069B2
(ja)
*
|
2013-11-07 |
2019-07-31 |
メモリアル スローン ケタリング キャンサー センター |
抗wt1/hla二重特異性抗体
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
EP3102681B1
(de)
|
2014-02-07 |
2023-10-04 |
McMaster University |
Trifunktionaler t-zell-antigenkoppler sowie verfahren und verwendungen davon
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
CA2943445A1
(en)
|
2014-03-26 |
2015-10-01 |
Cell Medica Switzerland Ag |
Binding members to tnf alpha
|
AU2015240595B2
(en)
|
2014-04-03 |
2020-02-27 |
Igm Biosciences, Inc. |
Modified J-chain
|
EP2930188A1
(de)
*
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunktionelles Antigen-bindendes Molekül
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
WO2016014974A2
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
TW201609812A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
最佳化之跨物種特異性雙特異性單鏈抗體構築體
|
EP3875481A1
(de)
|
2014-11-14 |
2021-09-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neutralisierende antikörper gegen ebola-virus-glycoprotein und deren verwendung
|
KR102614189B1
(ko)
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
CA2968987C
(en)
*
|
2014-12-08 |
2022-05-10 |
1Globe Biomedical Co., Ltd. |
Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
|
WO2016138160A1
(en)
|
2015-02-24 |
2016-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
US10787520B2
(en)
|
2015-03-04 |
2020-09-29 |
Igm Biosciences, Inc. |
Multimeric bispecific binding molecules specific for CD20 and CD3
|
PL3271389T3
(pl)
|
2015-03-20 |
2020-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizujące przeciwciała wiążące się z gp120 i ich stosowanie
|
MX2017013348A
(es)
|
2015-04-17 |
2018-08-01 |
Amgen Res Munich Gmbh |
Construcciones de anticuerpos biespecificos contra cdh3 y cd3.
|
FI3298033T4
(fi)
|
2015-05-18 |
2023-09-22 |
Tcr2 Therapeutics Inc |
Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
|
EP3302555A4
(de)
|
2015-05-29 |
2018-07-11 |
Amphivena Therapeutics, Inc. |
Verfahren zur verwendung bispezifischer cd33- und cd3-bindender proteine
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
CN108136012B
(zh)
|
2015-08-07 |
2022-10-04 |
伊麦吉纳博公司 |
靶向分子的抗原结合构建体
|
EP4129327A1
(de)
|
2015-08-28 |
2023-02-08 |
Amunix Pharmaceuticals, Inc. |
Chimäre polypeptidanordnung sowie verfahren zur herstellung und verwendung davon
|
CN108367004B
(zh)
|
2015-09-21 |
2022-09-13 |
阿帕特夫研究和发展有限公司 |
Cd3结合多肽
|
AU2016329197B2
(en)
|
2015-09-30 |
2021-01-21 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
WO2017059387A1
(en)
*
|
2015-09-30 |
2017-04-06 |
Igm Biosciences, Inc. |
Binding molecules with modified j-chain
|
CA2997809A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
WO2017070943A1
(zh)
*
|
2015-10-30 |
2017-05-04 |
江苏众红生物工程创药研究院有限公司 |
双特异性抗体、其制备方法和用途
|
CN115010805A
(zh)
|
2015-11-03 |
2022-09-06 |
美国政府(由卫生和人类服务部的部长所代表) |
Hiv-1 gp41中和抗体及其用途
|
CN108289952B
(zh)
|
2015-11-19 |
2021-02-05 |
雷维托普有限公司 |
用于对非所要细胞进行重定向杀灭的两组分系统的功能性抗体片段互补作用
|
BR112018003984A2
(pt)
|
2015-12-09 |
2018-09-25 |
Hoffmann La Roche |
anticorpos
|
CN108697746A
(zh)
|
2015-12-17 |
2018-10-23 |
皮斯奥克斯治疗公司 |
编码抗tcr复合体抗体或片段的病毒
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究(慕尼黑)公司 |
包含雙特異性抗體建構物之醫藥組合物
|
UA126657C2
(uk)
|
2016-02-03 |
2023-01-11 |
Емджен Рісерч (Мюнік) Ґмбг |
ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
|
BR112018015415A2
(pt)
|
2016-02-03 |
2018-12-18 |
Amgen Res Munich Gmbh |
célula t biespecífica de psma e cd3 de engate de construtos de anticorpos
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
KR20230041739A
(ko)
*
|
2016-03-08 |
2023-03-24 |
매버릭 테라퓨틱스, 인크. |
유도성 결합 단백질 및 사용 방법
|
WO2017167350A1
(en)
*
|
2016-03-30 |
2017-10-05 |
Horst Lindhofer |
Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
CA3059010A1
(en)
|
2016-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
EP3252078A1
(de)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
|
KR20190053835A
(ko)
|
2016-06-21 |
2019-05-20 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
SG11201811559WA
(en)
|
2016-06-27 |
2019-01-30 |
Univ California |
Cancer treatment combinations
|
WO2018009499A1
(en)
|
2016-07-06 |
2018-01-11 |
Celgene Corporation |
Antibodies with low immunogenicity and uses thereof
|
CN109715668A
(zh)
|
2016-08-02 |
2019-05-03 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重编程的组合物和方法
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
US20190194690A1
(en)
*
|
2016-08-29 |
2019-06-27 |
Psioxus Therapeutics Limited |
Adenovirus armed with bispecific t cell engager (bite)
|
UA126384C2
(uk)
|
2016-09-14 |
2022-09-28 |
Тенеобіо, Інк. |
Антитіло, яке зв'язує cd3
|
GB2564823B8
(en)
|
2016-10-07 |
2022-06-29 |
Tcr2 Therapeutics Inc |
Compositions and methods for TCR reprogramming using fusion proteins
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
|
CN110431151B
(zh)
|
2016-12-21 |
2023-07-18 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技(香港)有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
SG11201907299XA
(en)
|
2017-02-08 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
US11021535B2
(en)
|
2017-02-10 |
2021-06-01 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
CN110944661A
(zh)
|
2017-02-20 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
结合her2、nkg2d和cd16的蛋白质
|
CN108690138A
(zh)
*
|
2017-04-12 |
2018-10-23 |
鸿运华宁(杭州)生物医药有限公司 |
一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用
|
JP7325936B2
(ja)
|
2017-05-05 |
2023-08-15 |
アムジエン・インコーポレーテツド |
改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物
|
EP3409322A1
(de)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Behandlungsverfahren
|
EP3642237A2
(de)
|
2017-06-20 |
2020-04-29 |
Teneobio, Inc. |
Nur schwerketten-anti-bcma-antikörper
|
GB201710836D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Car T-Cells
|
GB201710835D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Antibodies
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
DK3661954T3
(da)
|
2017-08-03 |
2022-04-19 |
Amgen Inc |
Interleukin-21-muteiner og fremgangsmåder til behandling
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
BR112020004543A2
(pt)
|
2017-09-08 |
2020-09-08 |
Maverick Therapeutics, Inc. |
proteínas de ligação ativadas condicionalmente restritas
|
CN107501412A
(zh)
*
|
2017-10-11 |
2017-12-22 |
深圳精准医疗科技有限公司 |
突变型双特异性抗体及其应用
|
CA3078637A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
T cell-antigen coupler with y182t mutation and methods and uses thereof
|
WO2019075378A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
B-MATURATION ANTIGEN BINDING PROTEINS
|
GB201717966D0
(en)
*
|
2017-10-31 |
2017-12-13 |
Xenikos Bv |
Immunotoxins, formulations thereof and their use in medicine
|
AU2018383679A1
(en)
|
2017-12-11 |
2020-05-07 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
WO2019136029A1
(en)
|
2018-01-02 |
2019-07-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
MA51631A
(fr)
|
2018-01-12 |
2020-11-18 |
Amgen Inc |
Anticorps anti-pd1 et méthodes de traitement
|
EP3749346A4
(de)
|
2018-02-08 |
2021-12-15 |
Dragonfly Therapeutics, Inc. |
Gegen nkg2d-rezeptor gerichtete variable antikörperdomänen
|
RU2020130795A
(ru)
|
2018-02-21 |
2022-03-21 |
Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз |
Нейтрализующие антитела к env вич-1 и их применение
|
BR112020024351A2
(pt)
|
2018-06-01 |
2021-02-23 |
Novartis Ag |
moléculas de ligação contra bcma e usos das mesmas
|
US20220002398A1
(en)
*
|
2018-06-07 |
2022-01-06 |
Oncoone Research & Development Gmbh |
ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
|
KR20210028204A
(ko)
|
2018-07-02 |
2021-03-11 |
암젠 인크 |
항-steap1 항원 결합 단백질
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
AU2019313444A1
(en)
|
2018-07-30 |
2021-02-18 |
Amgen Inc. |
Prolonged administration of a bispecific antibody construct binding to CD33 and CD3
|
US20210284732A1
(en)
|
2018-07-31 |
2021-09-16 |
Amgen Research (Munich) Gmbh |
Dosing regimen for bcma-cd3 bispecific antibodies
|
TWI830761B
(zh)
|
2018-08-03 |
2024-02-01 |
德商安美基研究(慕尼黑)公司 |
針對cldn18.2和cd3之抗體構建體
|
WO2020047389A1
(en)
|
2018-08-31 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
CN110872356B
(zh)
*
|
2018-09-03 |
2023-06-13 |
广西慧宝源健康产业有限公司 |
双特异性抗体及其使用方法
|
AU2019346466A1
(en)
|
2018-09-25 |
2021-05-20 |
Harpoon Therapeutics, Inc. |
DLL3 binding proteins and methods of use
|
KR20210068408A
(ko)
|
2018-09-28 |
2021-06-09 |
암젠 인크 |
가용성 bcma에 대한 항체
|
TW202028245A
(zh)
|
2018-10-11 |
2020-08-01 |
美商英伊布里克斯公司 |
Dll3單域抗體及其治療性組合物
|
TW202021986A
(zh)
|
2018-10-11 |
2020-06-16 |
美商英伊布里克斯公司 |
5t4單域抗體及其治療性組合物
|
SG11202103275YA
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc |
Downstream processing of bispecific antibody constructs
|
JP7453219B2
(ja)
|
2018-10-11 |
2024-03-19 |
インヒブリックス, インコーポレイテッド |
Pd-1単一ドメイン抗体およびその治療用組成物
|
US20230124851A1
(en)
|
2018-10-11 |
2023-04-20 |
Inhibrx, lnc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
WO2020086635A1
(en)
|
2018-10-23 |
2020-04-30 |
Amgen Inc. |
Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions
|
US20230416385A1
(en)
|
2018-11-01 |
2023-12-28 |
Shandong New Time Pharmaceutical Co., Ltd. |
Bispecific antibody and use thereof
|
US20230037682A1
(en)
*
|
2018-12-04 |
2023-02-09 |
Novartis Ag |
Binding molecules against cd3 and uses thereof
|
WO2020132214A2
(en)
|
2018-12-20 |
2020-06-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
TW202043253A
(zh)
|
2019-01-28 |
2020-12-01 |
美商安進公司 |
藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
|
CN114390938A
(zh)
|
2019-03-05 |
2022-04-22 |
武田药品工业有限公司 |
受约束的条件性活化的结合蛋白
|
WO2020227228A2
(en)
|
2019-05-03 |
2020-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2020232303A1
(en)
*
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
WO2020232247A1
(en)
|
2019-05-14 |
2020-11-19 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
WO2020247852A1
(en)
|
2019-06-07 |
2020-12-10 |
Amgen Inc. |
Bispecific binding constructs
|
MX2021014644A
(es)
|
2019-06-13 |
2022-04-06 |
Amgen Inc |
Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
|
AR119746A1
(es)
|
2019-06-14 |
2022-01-05 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
AU2020299382A1
(en)
|
2019-07-02 |
2022-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind EGFRvIII and their use
|
WO2021041300A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
CA3152946A1
(en)
|
2019-09-10 |
2021-03-18 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
|
WO2021091906A1
(en)
|
2019-11-04 |
2021-05-14 |
Amgen Inc. |
Methods for treating leukemia
|
EP3819312A1
(de)
|
2019-11-10 |
2021-05-12 |
Amgen, Inc |
Dosierschema für anti-dll3-wirkstoffe
|
EP3819007A1
(de)
|
2019-11-11 |
2021-05-12 |
Amgen Research (Munich) GmbH |
Dosierschema für anti-bcma-wirkstoffe
|
AU2020381536A1
(en)
|
2019-11-13 |
2022-04-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
UY38995A
(es)
|
2019-12-20 |
2021-06-30 |
Amgen Inc |
Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
|
CN115279406A
(zh)
|
2020-01-13 |
2022-11-01 |
阿帕特夫研究和发展有限公司 |
蛋白质治疗剂的调配物
|
EP4090348A4
(de)
*
|
2020-01-13 |
2024-05-15 |
Univ California |
Verfahren zum behandeln von viralinfektionen
|
CN115666639A
(zh)
|
2020-01-13 |
2023-01-31 |
阿帕特夫研究和发展有限公司 |
用于防止治疗性蛋白吸附到药物递送系统部件的方法和组合物
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
US20230071627A1
(en)
|
2020-02-03 |
2023-03-09 |
Amgen Inc. |
Multivariate Bracketing Approach for Sterile Filter Validation
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
IL296601A
(en)
|
2020-03-19 |
2022-11-01 |
Amgen Inc |
Antibodies against mucin 17 and their uses
|
CN115715220A
(zh)
|
2020-04-29 |
2023-02-24 |
特尼奥生物股份有限公司 |
具有经修饰重链恒定区的多特异性重链抗体
|
JP2023527293A
(ja)
|
2020-05-19 |
2023-06-28 |
アムジエン・インコーポレーテツド |
Mageb2結合構築物
|
CA3183693A1
(en)
|
2020-05-29 |
2021-12-02 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
|
EP4161969A1
(de)
|
2020-06-04 |
2023-04-12 |
Amgen Inc. |
Bispezifische bindungskonstrukte
|
WO2022056267A1
(en)
|
2020-09-11 |
2022-03-17 |
Amgen Inc. |
Materials and methods to reduce protein aggregation
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
MX2023003041A
(es)
|
2020-09-16 |
2023-05-09 |
Amgen Inc |
Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
|
US20220168407A1
(en)
|
2020-11-05 |
2022-06-02 |
Dcprime B.V. |
Use of tumor-independent antigens in immunotherapies
|
BR112023008629A2
(pt)
|
2020-11-06 |
2023-10-03 |
Amgen Inc |
Construtos de polipeptídeos que se ligam seletivamente a cldn6 e cd3
|
IL301926A
(en)
|
2020-11-06 |
2023-06-01 |
Amgen Inc |
Antigen binding domain with reduced cleavage rate
|
AU2021374839A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
BR112023008670A2
(pt)
|
2020-11-06 |
2024-02-06 |
Amgen Inc |
Construtos polipeptídicos ligados à cd3
|
EP4243936A1
(de)
|
2020-11-10 |
2023-09-20 |
Amgen Inc. |
Verfahren zur verabreichung eines bcma x cd3-bindenden moleküls
|
US11617767B2
(en)
|
2020-11-20 |
2023-04-04 |
Simcere Innovation, Inc. |
Armed dual CAR-T compositions and methods for cancer immunotherapy
|
WO2022120033A1
(en)
|
2020-12-03 |
2022-06-09 |
Amgen Inc. |
Immunoglobuline constructs with multiple binding domains
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
EP4291226A1
(de)
|
2021-02-09 |
2023-12-20 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Antikörper gegen das spike-protein von coronaviren
|
EP4291306A1
(de)
|
2021-02-09 |
2023-12-20 |
University of Georgia Research Foundation, Inc. |
Menschliche monoklonale antikörper gegen pneumokokken-antigene
|
WO2022191971A1
(en)
|
2021-03-10 |
2022-09-15 |
Amgen Inc. |
Parallel chromatography systems and methods
|
AU2022234768A1
(en)
|
2021-03-10 |
2023-07-27 |
Amgen Inc. |
Methods for purification of recombinant proteins
|
AR125290A1
(es)
|
2021-04-02 |
2023-07-05 |
Amgen Inc |
Construcciones de unión a mageb2
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
|
IL307672A
(en)
|
2021-05-06 |
2023-12-01 |
Amgen Res Munich Gmbh |
CD20 and CD22 targeting antigen-binding molecules for use in proliferative diseases
|
EP4341289A1
(de)
|
2021-05-18 |
2024-03-27 |
Christian-Albrechts-Universität zu Kiel |
Costimulatorische multispezifische antikörper
|
EP4341291A1
(de)
|
2021-05-21 |
2024-03-27 |
Aptevo Research and Development LLC |
Dosierungsschemata für proteintherapeutika
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
CA3232223A1
(en)
|
2021-09-17 |
2023-03-23 |
Ying Fu |
Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
|
AU2022379497A1
(en)
|
2021-10-27 |
2024-05-02 |
Amgen Inc. |
Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy
|
TW202334221A
(zh)
|
2021-11-03 |
2023-09-01 |
德商安富美德有限公司 |
雙特異性cd16a結合劑
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023087255A1
(zh)
*
|
2021-11-19 |
2023-05-25 |
武汉友芝友生物制药股份有限公司 |
双特异性抗体及其应用
|
WO2023110918A1
(en)
|
2021-12-14 |
2023-06-22 |
Cdr-Life Ag |
Dual mhc-targeting t cell engager
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
WO2023164474A1
(en)
|
2022-02-23 |
2023-08-31 |
Amgen Inc. |
Cancer treatment targeting dll3
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
JP2024517042A
(ja)
|
2022-04-13 |
2024-04-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd20/抗cd3二重特異性抗体の薬学的組成物及び使用方法
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2023230626A2
(en)
*
|
2022-05-27 |
2023-11-30 |
Bighat Biosciences, Inc. |
Ph-selective anti-cd3 antibodies and use of the same
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
WO2024056758A1
(en)
|
2022-09-14 |
2024-03-21 |
Cdr-Life Ag |
Mage-a4 peptide dual t cell engagers
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
WO2024082269A1
(zh)
*
|
2022-10-21 |
2024-04-25 |
武汉友芝友生物制药股份有限公司 |
双特异性抗体在免疫细胞治疗方面的应用
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|